Immunocore Holdings plc (IMCR) FY2026 YTD Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-01-01 to 2026-06-30

Swipe to see the full flow
Immunocore Holdings plc cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Orange marks positive customer-advance and deferred-revenue changes that add to operating cash in the reconciliation. These are net changes, not gross customer receipts. Negative changes are neutral reconciliation adjustments; they do not by themselves identify cash payments. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income (loss) → Net cash from operating activities: $2,153,000.00Net income (loss) → Operating adjustments reconciliation: $10,010,000.00Increase in accrued expenses → Operating adjustments reconciliation: $18,698,000.00Share-based compensation expense → Operating adjustments reconciliation: $15,706,000.00Depreciation → Operating adjustments reconciliation: $1,974,000.00Non-cash lease expense → Operating adjustments reconciliation: $1,237,000.00Increase (decrease) in accounts payable → Operating adjustments reconciliation: $1,171,000.00Other → Operating adjustments reconciliation: $1,080,000.00Operating adjustments reconciliation → Increase in accounts receivable: $22,551,000.00Operating adjustments reconciliation → (Increase) decrease in prepayments and other current assets: $16,675,000.00Operating adjustments reconciliation → Unrealized gains on marketable securities: $4,847,000.00Operating adjustments reconciliation → Unrealized foreign exchange gains, net: $2,682,000.00Operating adjustments reconciliation → Decrease in operating lease liabilities: $2,224,000.00Operating adjustments reconciliation → Decrease in other operating assets: $605,000.00Operating adjustments reconciliation → Decrease in deferred revenue: $292,000.00Proceeds from exercise of share options → financing reconciliation: $17,141,000.00financing reconciliation → Net cash from financing activities: $17,141,000.00Proceeds from sale of marketable securities → investing reconciliation: $6,000,000.00investing reconciliation → Net cash from investing activities: $3,433,000.00investing reconciliation → Purchase of property and equipment: $2,567,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $467,709,000.00Net cash from operating activities → Cash sources and uses: $2,153,000.00Net cash from financing activities → Cash sources and uses: $17,141,000.00Net cash from investing activities → Cash sources and uses: $3,433,000.00Cash sources and uses → Exchange-rate effect: $5,516,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $484,920,000.00Net income (loss): $12,163,000.00Net income (loss)+$12.16 MShare-based compensation expense: $15,706,000.00Stock-based compensation+$15.71 MDecrease in operating lease liabilities: -$2,224,000.00Operating lease liabilities−$2.22 MDepreciation: $1,974,000.00Depreciation expense+$1.97 MUnrealized foreign exchange gains, net: -$2,682,000.00Unrealized FX gain & loss−$2.68 MOther: $1,080,000.00Other non-cash items+$1.08 MNon-cash lease expense: $1,237,000.00Operating lease amortization+$1.24 MIncrease in accounts receivable: -$22,551,000.00Accounts receivable−$22.55 M(Increase) decrease in prepayments and other current assets: -$16,675,000.00Prepaid & other assets−$16.68 MIncrease (decrease) in accounts payable: $1,171,000.00Accounts payable+$1.17 MIncrease in accrued expenses: $18,698,000.00Accrued liabilities+$18.70 MDecrease in other operating assets: -$605,000.00Other operating assets−$605.00 KUnrealized gains on marketable securities: -$4,847,000.00Unrealized securities gain/loss−$4.85 MDecrease in deferred revenue: -$292,000.00Deferred revenue−$292.00 KNet cash from operating activities: $2,153,000.00Operating cash+$2.15 MOperating adjustments reconciliation: $49,876,000.00Proceeds from exercise of share options: $17,141,000.00Stock option exercises+$17.14 MNet cash from financing activities: $17,141,000.00Financing cash+$17.14 Mfinancing reconciliation: $17,141,000.00Proceeds from sale of marketable securities: $6,000,000.00Marketable securities proceeds+$6.00 MPurchase of property and equipment: -$2,567,000.00PP&E purchases−$2.57 MPurchase of marketable securities: $0.00Net cash from investing activities: $3,433,000.00Investing cash+$3.43 Minvesting reconciliation: $6,000,000.00Cash sources and uses: $490,436,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $467,709,000.00Beginning cash$467.71 MEnding cash: Cash, cash equivalents, and restricted cash: $484,920,000.00Ending cash$484.92 MExchange-rate effect: -$5,516,000.00FX effect−$5.52 MCASH RECONCILIATIONOperatingflowsFinancingflowsInvestingflowsFree cash flow−$414.00 KOperating cash − cash spent on PP&ECash flow / Net income0.18×Operating cash flow ÷ net incomeNet cash change+$17.21 MEnding cash − beginning cash
Chart details

Immunocore Holdings plc cash flow reconciliation, Jan 1, 2026 through Jun 30, 2026

Cash flows for Jan 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Dec 31, 2025. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Dec 31, 2025
467,709,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
2,153,000 US dollars. Net cash provided.
Net income (loss)
12,163,000 US dollars
Share-based compensation expense
15,706,000 US dollars
Decrease in operating lease liabilities
negative 2,224,000 US dollars
Depreciation
1,974,000 US dollars
Unrealized foreign exchange gains, net
negative 2,682,000 US dollars
Other
1,080,000 US dollars
Non-cash lease expense
1,237,000 US dollars
Increase in accounts receivable
negative 22,551,000 US dollars
(Increase) decrease in prepayments and other current assets
negative 16,675,000 US dollars
Increase (decrease) in accounts payable
1,171,000 US dollars
Increase in accrued expenses
18,698,000 US dollars
Decrease in other operating assets
negative 605,000 US dollars
Unrealized gains on marketable securities
negative 4,847,000 US dollars
Decrease in deferred revenue
negative 292,000 US dollars
Investing activities
3,433,000 US dollars. Net cash provided.
Proceeds from sale of marketable securities
6,000,000 US dollars
Purchase of property and equipment
negative 2,567,000 US dollars
Purchase of marketable securities
0 US dollars
Financing activities
17,141,000 US dollars. Net cash provided.
Proceeds from exercise of share options
17,141,000 US dollars
Operating adjustment reconciliation
49,876,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
17,141,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
6,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 5,516,000 US dollars
Ending cash on Jun 30, 2026
484,920,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
490,436,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
17,211,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.18×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
2,153,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
2,567,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 414,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $2.15M of net income directly to operating cash and $10.01M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 2,153,000 US dollars minus 2,567,000 US dollars equals negative 414,000 US dollars.
Immunocore Holdings plc (IMCR) FY2026 YTD Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!